eli lilly weight loss

Order byBest matchMost fresh

Zepbound beats Wegovy for weight loss

Top News

Overview

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. The data is the first head-to-head trial comparing the wildly popular medicines,

· 2d · on MSN

· 1d · on MSN

Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

The Economist · 6d

Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown

What is the most effective weight loss drug?

drug maker Eli Lilly put its own weight loss drug Zepbound against the popular drug Wegovy, and Zepbound outperformed, causing 6% more weight loss than its competitor.

· 1d

New study compares Wegovy and Zepbound for the first time

· 2d

Study finds Zepbound may help people lose more weight than Wegovy

15hon MSN

This GLP-1 Is the Most Effective for Weight Loss, Study Says

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

STAT6d

Compounders lose legal battle with FDA over removal of Eli Lilly’s weight loss drug from a shortage list

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes drugs from compounding pharmacies.

KDFW1d

Zepbound vs. Wegovy: Here's which weight loss drug worked best in first trial

According to a study funded by Eli Lilly, the trial revealed that participants taking tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds, while those who took semaglutide, or Wegovy, lost about 33 pounds. The two weight-loss drugs are ...

13h

Why Weight-Loss Developer Stocks Tumbled on Tuesday

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement levels. The company most associated with obesity treatments, Denmark-based Novo Nordisk (NYSE: NVO),